Bioavailability and swallowability of an age-appropriate, delayed-release mesalamine formulation in healthy volunteers
Abhijeet Jakate,1 Brian McNamee,2 Donald Burkindine31Clinical Pharmacology, Allergan plc, Madison, NJ, USA; 2Clinical Pharmacology, Allergan Biologics Ltd, Liverpool, UK; 3QPS Bio-Kinetic, Springfield, MO, USAObjective: san jose sharks trucker hat Delayed-release mesalamine 400 mg capsules containing four 100 mg tablets have been developed for chil